{"id":21685,"date":"2023-12-20T08:23:47","date_gmt":"2023-12-20T07:23:47","guid":{"rendered":"https:\/\/ggba.swiss\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/"},"modified":"2023-12-20T08:26:56","modified_gmt":"2023-12-20T07:26:56","slug":"usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/","title":{"rendered":"USD 4,2 millions pour d\u00e9velopper le traitement contre la maladie d&rsquo;Alzheimer de GliaPharm"},"content":{"rendered":"\n<p>Fond\u00e9e en 2017, <a href=\"https:\/\/gliapharm.com\/\">GliaPharm<\/a> se sp\u00e9cialise dans le d\u00e9veloppement de traitements pour les maladies neurologiques en se concentrant sur la fonction des cellules gliales. Leur plateforme interne de d\u00e9couverte de m\u00e9dicaments, <a href=\"https:\/\/gliapharm.com\/gliaxtm\/\">GliaX<\/a>, a produit un pipeline de compos\u00e9s con\u00e7us pour am\u00e9liorer le m\u00e9tabolisme \u00e9nerg\u00e9tique du cerveau, un facteur critique dans les maladies neurod\u00e9g\u00e9n\u00e9ratives.<\/p>\n\n\n\n<p>La maladie d&rsquo;Alzheimer, caract\u00e9ris\u00e9e par une r\u00e9duction de l&rsquo;absorption du glucose dans le cerveau ou hypom\u00e9tabolisme, ne dispose actuellement d&rsquo;aucun traitement sp\u00e9cifique pour rem\u00e9dier \u00e0 ce d\u00e9clin m\u00e9tabolique. Le candidat principal de GliaPharm, GP-119, est une petite mol\u00e9cule active par voie orale qui cible ce probl\u00e8me. L&rsquo;investissement de USD 4,2 millions soutiendra la progression du GP-119 dans les \u00e9tudes d&rsquo;habilitation IND (Investigational New Drug) \/ CTA (Clinical Trial Application), essentielles pour obtenir l&rsquo;approbation des essais cliniques par les agences r\u00e9glementaires telles que la FDA aux Etats-Unis et l&rsquo;EMA en Europe.<\/p>\n\n\n\n<p>Le Dr Howard Fillit, cofondateur et directeur scientifique de l&rsquo;<a href=\"https:\/\/www.alzdiscovery.org\/\">ADDF<\/a>, a soulign\u00e9 l&rsquo;importance de ce d\u00e9veloppement : \u00ab&nbsp;Le d\u00e9veloppement de nouveaux m\u00e9dicaments qui r\u00e9gulent le m\u00e9tabolisme c\u00e9r\u00e9bral dans les corps vieillissants, comme le GP-119 de GliaPharm, est une approche prometteuse pour le traitement de la maladie d&rsquo;Alzheimer et des d\u00e9mences apparent\u00e9es. Nous esp\u00e9rons d\u00e9velopper un arsenal de m\u00e9dicaments capables de stopper la maladie dans son \u00e9lan gr\u00e2ce \u00e0 la th\u00e9rapie combin\u00e9e et \u00e0 la m\u00e9decine de pr\u00e9cision.&nbsp;\u00bb<\/p>\n\n\n\n<p>Ambroise Magistretti, co-CEO et co-fondatrice de GliaPharm, a exprim\u00e9 sa gratitude pour l&rsquo;investissement de l&rsquo;ADDF, reconnaissant qu&rsquo;il s&rsquo;agit d&rsquo;une forte approbation de leur programme sur la maladie d&rsquo;Alzheimer. Charles Finsterwald, CSO et co-fondateur de GliaPharm, a ajout\u00e9 que le soutien de l&rsquo;ADDF est crucial pour faire avancer leur programme principal \u00e0 travers les \u00e9tudes r\u00e9glementaires pr\u00e9cliniques, pr\u00e9parant ainsi le terrain pour des essais cliniques ult\u00e9rieurs. Il a \u00e9galement soulign\u00e9 la strat\u00e9gie de l&rsquo;ADDF de soutenir des solutions th\u00e9rapeutiques nouvelles et potentiellement compl\u00e9mentaires pour la maladie d&rsquo;Alzheimer, y compris l&rsquo;approche de GliaPharm pour s&rsquo;attaquer \u00e0 l&rsquo;hypom\u00e9tabolisme c\u00e9r\u00e9bral.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GliaPharm, une spin-off de l&rsquo;EPFL, a obtenu un investissement de USD 4,2 millions de l&rsquo;Alzheimer&rsquo;s Drug Discovery Foundation (ADDF) pour faire progresser son traitement de pointe contre la maladie d&rsquo;Alzheimer \u00e0 travers des \u00e9tudes pr\u00e9cliniques cruciales.<\/p>\n","protected":false},"author":6,"featured_media":21682,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1188,1141,1171,1142],"class_list":["post-21685","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-personalized-medicine-fr-2","tag-pharma-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>USD 4,2M pour le traitement contre Alzheimer de GliaPharm<\/title>\n<meta name=\"description\" content=\"GliaPharm a obtenu un investissement de USD 4,2 millions de l&#039;Alzheimer&#039;s Drug Discovery Foundation (ADDF).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"USD 4,2M pour le traitement contre Alzheimer de GliaPharm\" \/>\n<meta property=\"og:description\" content=\"GliaPharm a obtenu un investissement de USD 4,2 millions de l&#039;Alzheimer&#039;s Drug Discovery Foundation (ADDF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-20T07:23:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-20T07:26:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"USD 4,2 millions pour d\u00e9velopper le traitement contre la maladie d&rsquo;Alzheimer de GliaPharm\",\"datePublished\":\"2023-12-20T07:23:47+00:00\",\"dateModified\":\"2023-12-20T07:26:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/\"},\"wordCount\":396,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Personalized Medicine\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/\",\"name\":\"USD 4,2M pour le traitement contre Alzheimer de GliaPharm\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg\",\"datePublished\":\"2023-12-20T07:23:47+00:00\",\"dateModified\":\"2023-12-20T07:26:56+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"GliaPharm a obtenu un investissement de USD 4,2 millions de l'Alzheimer's Drug Discovery Foundation (ADDF).\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"Ce financement et le partenariat avec l'ADDF placent GliaPharm \u00e0 l'avant-garde du d\u00e9veloppement de traitements efficaces contre la maladie d'Alzheimer, offrant un nouvel espoir dans la lutte contre cette maladie neurod\u00e9g\u00e9n\u00e9rative difficile.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"USD 4,2 millions pour d\u00e9velopper le traitement contre la maladie d&#8217;Alzheimer de GliaPharm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"USD 4,2M pour le traitement contre Alzheimer de GliaPharm","description":"GliaPharm a obtenu un investissement de USD 4,2 millions de l'Alzheimer's Drug Discovery Foundation (ADDF).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/","og_locale":"fr_FR","og_type":"article","og_title":"USD 4,2M pour le traitement contre Alzheimer de GliaPharm","og_description":"GliaPharm a obtenu un investissement de USD 4,2 millions de l'Alzheimer's Drug Discovery Foundation (ADDF).","og_url":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-12-20T07:23:47+00:00","article_modified_time":"2023-12-20T07:26:56+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"USD 4,2 millions pour d\u00e9velopper le traitement contre la maladie d&rsquo;Alzheimer de GliaPharm","datePublished":"2023-12-20T07:23:47+00:00","dateModified":"2023-12-20T07:26:56+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/"},"wordCount":396,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg","keywords":["Biotech","Financing","Healthcare","Personalized Medicine","Pharma","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/","url":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/","name":"USD 4,2M pour le traitement contre Alzheimer de GliaPharm","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg","datePublished":"2023-12-20T07:23:47+00:00","dateModified":"2023-12-20T07:26:56+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"GliaPharm a obtenu un investissement de USD 4,2 millions de l'Alzheimer's Drug Discovery Foundation (ADDF).","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg","width":2360,"height":1622,"caption":"Ce financement et le partenariat avec l'ADDF placent GliaPharm \u00e0 l'avant-garde du d\u00e9veloppement de traitements efficaces contre la maladie d'Alzheimer, offrant un nouvel espoir dans la lutte contre cette maladie neurod\u00e9g\u00e9n\u00e9rative difficile."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/usd-42-millions-pour-developper-le-traitement-contre-la-maladie-dalzheimer-de-gliapharm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"USD 4,2 millions pour d\u00e9velopper le traitement contre la maladie d&#8217;Alzheimer de GliaPharm"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/21685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=21685"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/21685\/revisions"}],"predecessor-version":[{"id":21687,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/21685\/revisions\/21687"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/21682"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=21685"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=21685"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=21685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}